» Authors » Naser Ahmadbeigi

Naser Ahmadbeigi

Explore the profile of Naser Ahmadbeigi including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 53
Citations 580
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Ashraf H, Kosari F, Khorsand A, Muhammadnejad S, Mansouri V, Muhammadnejad A, et al.
Arch Iran Med . 2025 Feb; 27(12):683-692. PMID: 39891456
Background: Xenogeneic graft-versus-host disease (xGvHD) is an inevitable confounder of preclinical evaluation of adoptive immunotherapies on tumor-bearing immunodeficient mouse models. This study was designed to appraise the clinical and histopathological...
2.
Monzavi S, Muhammadnejad S, Mansouri V, Ashraf H, Ahmadbeigi N
Animal Model Exp Med . 2024 Nov; 8(1):20-29. PMID: 39601130
Human-derived tumor models are essential for preclinical development of new anticancer drug entities. Generating animal models bearing tumors of human origin, such as patient-derived or cell line-derived xenograft tumors, is...
3.
Molaei Z, Jabbarpour Z, Omidkhoda A, Ahmadbeigi N
Stem Cell Res Ther . 2024 Jul; 15(1):233. PMID: 39075609
Gene manipulation of hematopoietic stem cells (HSCs) using the CRISPR/Cas system as a potent genome editing tool holds immense promise for addressing hematologic disorders. An essential hurdle in advancing this...
4.
Moradi V, Khodabandehloo E, Alidadi M, Omidkhoda A, Ahmadbeigi N
Front Oncol . 2024 Jun; 14:1388475. PMID: 38912057
CAR-T cell therapy has shown remarkable promise in treating B-cell malignancies, which has sparked optimism about its potential to treat other types of cancer as well. Nevertheless, the Expectations of...
5.
Soufizadeh P, Mansouri V, Ahmadbeigi N
Lab Anim Res . 2024 Apr; 40(1):17. PMID: 38649954
Scientific progress heavily relies on rigorous research, adherence to scientific standards, and transparent reporting. Animal models play a crucial role in advancing biomedical research, especially in the field of gene...
6.
Rayati M, Mansouri V, Ahmadbeigi N
Heliyon . 2024 Mar; 10(5):e27087. PMID: 38439834
Glioblastoma multiforme (GBM) is one of the most lethal cancers with a poor prognosis. Over the past century since its initial discovery and medical description, the development of effective treatments...
7.
Moradi V, Omidkhoda A, Ahmadbeigi N
Biomed Pharmacother . 2023 Nov; 169:115888. PMID: 37979380
The advent of chimeric antigen receptor T cells (CAR-T cells) has made a tremendous revolution in the era of cancer immunotherapy, so that since 2017 eight CAR-T cell products have...
8.
Sahlolbei M, Azangou-Khyavy M, Khanali J, Khorsand B, Shiralipour A, Ahmadbeigi N, et al.
Heliyon . 2023 Oct; 9(9):e19763. PMID: 37809446
Background: Recent evidence suggests that B cells and autoantibodies have a substantial role in the pathogenesis of Multiple sclerosis. T cells could be engineered to express chimeric autoantibody receptors (CAARs),...
9.
Monzavi S, Hamidieh A, Vasei M, Ai J, Ahmadbeigi N, Arshadi H, et al.
Bioimpacts . 2023 Sep; 13(5):415-424. PMID: 37736339
Introduction: T cells that recognize WT1 peptides have been shown to efficiently eliminate WT1-expressing tumor cells. This study was designed to investigate the feasibility of isolating WT1-reactive T cells from...
10.
Jabbarpour Z, Aghayan S, Moradzadeh K, Ghaffari S, Ahmadbeigi N
BMC Immunol . 2023 Sep; 24(1):28. PMID: 37658313
Background: Cytokine-induced killer (CIK) cells have shown promising results in adoptive immunotherapy. However, serum may play a determining role in the large-scale expansion of these cells for clinical applications. According...